575 related articles for article (PubMed ID: 22464322)
1. Malignant glioma: lessons from genomics, mouse models, and stem cells.
Chen J; McKay RM; Parada LF
Cell; 2012 Mar; 149(1):36-47. PubMed ID: 22464322
[TBL] [Abstract][Full Text] [Related]
2. An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
Ius T; Ciani Y; Ruaro ME; Isola M; Sorrentino M; Bulfoni M; Candotti V; Correcig C; Bourkoula E; Manini I; Pegolo E; Mangoni D; Marzinotto S; Radovic S; Toffoletto B; Caponnetto F; Zanello A; Mariuzzi L; Di Loreto C; Beltrami AP; Piazza S; Skrap M; Cesselli D
Neuro Oncol; 2018 May; 20(6):776-787. PubMed ID: 29228370
[TBL] [Abstract][Full Text] [Related]
3. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
[TBL] [Abstract][Full Text] [Related]
4. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion.
Edwards LA; Woolard K; Son MJ; Li A; Lee J; Ene C; Mantey SA; Maric D; Song H; Belova G; Jensen RT; Zhang W; Fine HA
J Natl Cancer Inst; 2011 Aug; 103(15):1162-78. PubMed ID: 21771732
[TBL] [Abstract][Full Text] [Related]
5. Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation.
Xu J; Zhang Z; Qian M; Wang S; Qiu W; Chen Z; Sun Z; Xiong Y; Wang C; Sun X; Zhao R; Xue H; Li G
J Exp Clin Cancer Res; 2020 Apr; 39(1):59. PubMed ID: 32252802
[TBL] [Abstract][Full Text] [Related]
6. TNIP1-mediated TNF-α/NF-κB signalling cascade sustains glioma cell proliferation.
Lei Q; Gu H; Li L; Wu T; Xie W; Li M; Zhao N
J Cell Mol Med; 2020 Jan; 24(1):530-538. PubMed ID: 31691497
[TBL] [Abstract][Full Text] [Related]
7. GLIS family zinc finger 3 promoting cell malignant behaviors and NF-κB signaling in glioma.
Liu Z; Liu L; Qi Y; Li H; Pan S
Brain Res; 2021 Nov; 1770():147623. PubMed ID: 34403660
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells and the biology of brain tumors.
Flores DG; Ledur PF; Abujamra AL; Brunetto AL; Schwartsmann G; Lenz G; Roesler R
Curr Stem Cell Res Ther; 2009 Dec; 4(4):306-13. PubMed ID: 19804368
[TBL] [Abstract][Full Text] [Related]
9. The role of glioma stem cells in glioma tumorigenesis.
Yin CL; Lv SQ; Chen XY; Guo H
Front Biosci (Landmark Ed); 2014 Jan; 19(5):818-24. PubMed ID: 24389226
[TBL] [Abstract][Full Text] [Related]
10. Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.
Stoltz K; Sinyuk M; Hale JS; Wu Q; Otvos B; Walker K; Vasanji A; Rich JN; Hjelmeland AB; Lathia JD
Neuro Oncol; 2015 Mar; 17(3):361-71. PubMed ID: 25416826
[TBL] [Abstract][Full Text] [Related]
11. Gliomagenesis: genetic alterations and mouse models.
Holland EC
Nat Rev Genet; 2001 Feb; 2(2):120-9. PubMed ID: 11253051
[TBL] [Abstract][Full Text] [Related]
12. Brain tumor stem cells as therapeutic targets in models of glioma.
Laks DR; Visnyei K; Kornblum HI
Yonsei Med J; 2010 Sep; 51(5):633-40. PubMed ID: 20635435
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of malignant glial tumors.
Jones TS; Holland EC
Toxicol Pathol; 2011 Jan; 39(1):158-66. PubMed ID: 21078918
[TBL] [Abstract][Full Text] [Related]
14. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
15. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
16. TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets.
Song L; Liu L; Wu Z; Li Y; Ying Z; Lin C; Wu J; Hu B; Cheng SY; Li M; Li J
J Clin Invest; 2012 Oct; 122(10):3563-78. PubMed ID: 23006329
[TBL] [Abstract][Full Text] [Related]
17. FABP5 enhances malignancies of lower-grade gliomas via canonical activation of NF-κB signaling.
Wang Y; Wahafu A; Wu W; Xiang J; Huo L; Ma X; Wang N; Liu H; Bai X; Xu D; Xie W; Wang M; Wang J
J Cell Mol Med; 2021 May; 25(9):4487-4500. PubMed ID: 33837625
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers in glioma.
Ludwig K; Kornblum HI
J Neurooncol; 2017 Sep; 134(3):505-512. PubMed ID: 28233083
[TBL] [Abstract][Full Text] [Related]
19. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
[TBL] [Abstract][Full Text] [Related]
20. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.
Guichet PO; Masliantsev K; Tachon G; Petropoulos C; Godet J; Larrieu D; Milin S; Wager M; Karayan-Tapon L
J Pathol; 2018 Oct; 246(2):205-216. PubMed ID: 30009411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
